Vir Biotechnology, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Vir Biotechnology, Inc. (VIR) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 10.37 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- Vir Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 10.37M shares, a 36.35% decline year-over-year.
- Vir Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 18.81M shares, a 4.66% increase year-over-year.
- Vir Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 14.79M shares, a 3.10% decline year-over-year.
- Vir Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 16.30M shares, a 7.17% decline year-over-year.
- Vir Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 14.32M shares, a 1.80% decline from fiscal 2024.
- Vir Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 14.59M shares, a 10.97% decline from fiscal 2023.
- Vir Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 16.38M shares, a 42.47% increase from fiscal 2022.
- Vir Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 11.50M shares, a 67.83% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 10.37M shares 10-Q · filed 2026-08-05 | 17.40M shares 10-Q · filed 2026-08-05 | |||||
| 2026-03-31 | 18.81M shares 10-Q · filed 2026-05-07 | ||||||
| 2025-12-31 | 14.32M shares 10-K · filed 2026-02-23 | ||||||
| 2025-09-30 | 14.79M shares 10-Q · filed 2025-11-05 | 14.79M shares 10-Q · filed 2025-11-05 | |||||
| 2025-06-30 | 16.30M shares 10-Q · filed 2026-08-05 | 16.30M shares 10-Q · filed 2026-08-05 | |||||
| 2025-03-31 | 17.97M shares 10-Q · filed 2026-05-07 | ||||||
| 2024-12-31 | 14.59M shares 10-K · filed 2026-02-23 | ||||||
| 2024-09-30 | 15.27M shares 10-Q · filed 2025-11-05 | 16.52M shares 10-Q · filed 2024-11-04 | 15.27M shares 10-Q · filed 2025-11-05 | 17.43M shares 10-Q · filed 2024-11-04 | |||
| 2024-06-30 | 17.56M shares 10-Q · filed 2025-08-06 | 15.25M shares 10-Q · filed 2024-08-01 | 17.06M shares 10-Q · filed 2024-08-01 | ||||
| 2024-03-31 | 16.54M shares 10-Q · filed 2025-05-08 | ||||||
| 2023-12-31 | 16.38M shares 10-K · filed 2026-02-23 | ||||||
| 2023-09-30 | 15.73M shares 10-Q · filed 2024-11-04 | 15.10M shares 10-Q · filed 2024-11-04 | |||||
| 2023-06-30 | 13.85M shares 10-Q · filed 2024-08-01 | 13.49M shares 10-Q · filed 2024-08-01 | |||||
| 2023-03-31 | 12.17M shares 10-Q · filed 2024-05-03 | ||||||
| 2022-12-31 | 11.50M shares 10-K · filed 2025-02-27 | ||||||
| 2022-09-30 | 10.58M shares 10-Q · filed 2023-11-03 | 11.44M shares 10-Q · filed 2023-11-03 | |||||
| 2022-06-30 | 14.38M shares 10-Q · filed 2023-08-04 | 11.30M shares 10-Q · filed 2023-08-04 | 11.30M shares 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | 9.60M shares 10-Q · filed 2023-05-08 | ||||||
| 2021-12-31 | 6.85M shares 10-K · filed 2024-02-26 | ||||||
| 2021-09-30 | 7.38M shares 10-Q · filed 2022-11-03 | 7.45M shares 10-Q · filed 2021-11-04 | 6.30M shares 10-Q · filed 2022-11-03 | 6.38M shares 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | 7.17M shares 10-Q · filed 2022-08-09 | 11.84M shares 10-Q · filed 2022-08-09 | |||||
| 2021-03-31 | 12.38M shares 10-Q · filed 2021-05-06 | ||||||
| 2020-12-31 | 9.89M shares 10-K · filed 2023-02-28 | ||||||
| 2020-09-30 | 9.74M shares 10-Q · filed 2021-11-04 | 9.74M shares 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | 9.78M shares 10-Q · filed 2021-08-05 | 9.78M shares 10-Q · filed 2021-08-05 | |||||
| 2020-03-31 | 9.66M shares 10-Q · filed 2021-05-06 | ||||||
| 2019-12-31 | 9.51M shares 10-K · filed 2022-02-28 | ||||||
| 2019-09-30 | 97.36M shares 10-Q · filed 2020-11-10 | ||||||
| 2019-06-30 | 98.32M shares 10-Q · filed 2020-08-11 | ||||||
| 2019-03-31 | 98.29M shares 10-Q · filed 2020-05-12 | ||||||
| 2018-12-31 | 80.01M shares 10-K · filed 2021-02-25 | ||||||
| 2018-09-30 | 80.11M shares 10-Q · filed 2019-11-19 | ||||||
| 2017-12-31 | 75.73M shares 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |